AI assistant
Sending…
Aura Biosciences, Inc. — Director's Dealing 2021
Nov 2, 2021
33080_dirs_2021-11-02_a10f71c2-3817-42e6-909e-c0889a7abd01.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aura Biosciences, Inc. (AURA)
CIK: 0001501796
Period of Report: 2021-11-02
Reporting Person: Johnson David Michael (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-11-02 | Common Stock | C | 139672 | $0.00 | Acquired | 139672 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-11-02 | Series E Convertible Preferred Stock | $ | C | 139672 | Disposed | Common Stock (139672) | Indirect |
Footnotes
F1: The Series E Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021.
F2: Velosity Capital Management LLC is an entity that the reporting person is the sole member of.